Please Wait.....
Report
Small Cell Lung Cancer (SCLC) Market Report and Forecast 2024-2032
Market Report (7 days) I 2024-02-13 I 180 Pages I EMR Inc.
Small Cell Lung Cancer (SCLC) Market Report and Forecast 2024-2032
Small Cell Lung Cancer (SCLC) Market Outlook
The small cell lung cancer (SCLC) market size in the 7 major markets is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032. The growth of the market can be attributed to the rising prevalence of small cell lung cancer (SCLC) across these markets.
Small Cell Lung Cancer (SCLC): Introduction
Small cell lung cancer is a rare and lethal lung cancer that grows aggressively. It can affect anyone, but people with a long history of smoking tobacco are most susceptible to SCLC. It can be treated with a high chance of living a healthy life if the disease is detected in the early stages. The only way one can prevent small cell lung cancer is by not smoking.
Small Cell Lung Cancer (SCLC) Market Analysis
The small cell lung cancer (SCLC) market demand is witnessing significant growth due to the increased prevalence of small cell lung cancer (SCLC) among people. The continuous comprehension by the FDA in closing a crucial gap of unmet needs is a major factor expected to be responsible for the growth of the market in the forecast period. For example, the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R). It has been developed by a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. Such designations by the FDA are expected to result in innovation among biotech companies dedicated to developing treatments for people suffering from this disease, further bolstering the small cell lung cancer (SCLC) market growth.
Additionally, to find an appropriate treatment for this life-threatening disease, scientists are continuously engaged in research to discover therapeutics that could act effectively in the treatment or prevention of SCLC. Pharmaceutical companies are participating equally in these research activities. For example, Chugai Pharmaceutical Co., Ltd., Japan's pioneering research-based pharmaceutical company with strengths in biotechnology products, recently declared that their phase III BEAT-SC study, evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and platinum-based chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), met its primary endpoint of progression-free survival (P89uuFS).
Positive results from such studies stand fair chances to play a crucial role in the development of new therapeutics for effective treatment of SCLC provide better patient outcomes, and act as a catalyst in the demand for such treatments, propelling the market growth in the forecast period.
Small Cell Lung Cancer (SCLC) Market Segmentations
Market Breakup by Treatment
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Others
Market Breakup by Route of Administration
- Oral
- Intravenous
- Others
Market Breakup by Gender
- Male
- Female
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Centres
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
o Germany
o France
o Italy
o Spain
o United Kingdom
- Japan
Small Cell Lung Cancer (SCLC) Market Overview
The market growth is driven by the increasing prevalence of small cell lung cancer (SCLC). The rising number of smokers across the world and especially these 7 regions are the major reasons for the increased prevalence of this condition. Lung cancer is the second most diagnosed cancer worldwide. The market growth is further driven by ongoing research and innovations to bring new treatments for cures and diagnostics to enable early detection of this deadly disease. Such innovations and advancements are expected to exhibit an upward trajectory for the forecast cast and contribute to the small cell lung cancer (SCLC) market share. The increasing initiatives to spread awareness about the lethal nature of tobacco smoking are propelling the market further.
Geographically, the United States is dominating the market due to the increased prevalence of the condition. It is estimated that approximately 14% of people who are diagnosed with lung cancer in the United States have SCLC. The market growth is further driven by the increased adaptation of advanced technologies and the availability of healthcare professionals who are aware of SCLC and its symptoms due to which early detection is possible in patients.
Small Cell Lung Cancer (SCLC) Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Pfizer Inc.
- GSK plc
- Novartis AG
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Merck & Co. Inc.
- CLOVIS Oncology
- Johnson & Johnson Private Limited
- Lilly
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
FAQ
- What is the small cell lung cancer (SCLC) market forecast outlook for 2024-2032?
The market is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032, likely to be driven by the increased prevalence of small cell lung cancer (SCLC).
- What are the major factors aiding the small cell lung cancer (SCLC) market demand?
The major factors driving the market demand include increased tobacco smoking, coupled with the increased prevalence of small cell lung cancer (SCLC) across the major markets.
- What are the major small cell lung cancer (SCLC) market trends?
The high investments by the government and increasing initiatives by non-government organizations such as WHO to increase awareness about the disadvantages of tobacco smoking are among the major trends influencing the market growth.
- What are the major regional markets for small cell lung cancer (SCLC), according to the EMR report?
The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan. EU-4 includes Germany, France, Italy, and Spain.
- What are the treatments available in the market?
Treatments for SCLC include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and others.
- What are the various routes of administration for SCLC treatments?
Various routes of administration include oral, intravenous, and others.
- Which genders are affected by the condition?
The genders can be divided into male and female.
- Who are the end users in the market?
End users in the market include hospitals, home care, specialty centers, and others.
- What are the various distribution channels in the market?
Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies.
- Who are the key players in the small cell lung cancer (SCLC) market?
Key players involved in the market are Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Mylan N.V., Pfizer Inc., GSK plc, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Merck & Co. Inc., CLOVIS Oncology, Johnson & Johnson Private Limited, and Lilly.
Meta Description
The small cell lung cancer (SCLC) market size is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Small Cell Lung Cancer (SCLC) Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Small Cell Lung Cancer (SCLC) Epidemiology Analysis - 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.1 Germany Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.2 France Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.3 Italy Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.4 Spain Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.4 Japan Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
6 Small Cell Lung Cancer (SCLC) Market Overview - 7MM
6.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
6.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
7 Small Cell Lung Cancer (SCLC) Market Landscape - 7MM
7.1 Small Cell Lung Cancer (SCLC): Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Small Cell Lung Cancer (SCLC) Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Route of Administration
8 Small Cell Lung Cancer (SCLC) Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Small Cell Lung Cancer (SCLC) Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Small Cell Lung Cancer (SCLC) Market Segmentation - 7MM
11.1 Small Cell Lung Cancer (SCLC) Market by Diagnosis
11.1.1 Market Overview
11.1.2 Imaging Tests
11.1.3 Pulmonary Function Test
11.1.4 Lung Tissue Analysis
11.1.5 Others
11.2 Small Cell Lung Cancer (SCLC) Market by Treatment
11.2.1 Market Overview
11.2.2 Chemotherapy
11.2.3 Immunotherapy
11.2.4 Targeted Therapy
11.2.5 Radiation Therapy
11.2.6 Others
11.3 Small Cell Lung Cancer (SCLC) Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Intravenous
11.3.4 Others
11.4 Small Cell Lung Cancer (SCLC) Market by Gender
11.4.1 Market Overview
11.4.2 Male
11.4.3 Female
11.5 Small Cell Lung Cancer (SCLC) Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Homecare
11.5.4 Specialty Centres
11.5.5 Others
11.6 Small Cell Lung Cancer (SCLC) Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Online Pharmacy
11.6.4 Retail Pharmacy
11.7 Small Cell Lung Cancer (SCLC) Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Small Cell Lung Cancer (SCLC) Market
12.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
12.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
12.3 Small Cell Lung Cancer (SCLC) Market by Type
12.4 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13 EU-4 and United Kingdom Small Cell Lung Cancer (SCLC) Market
13.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
13.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
13.3 Germany Small Cell Lung Cancer (SCLC) Market Overview
13.3.1 Small Cell Lung Cancer (SCLC) Market by Type
13.3.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.4 France Small Cell Lung Cancer (SCLC) Market Overview
13.4.1 Small Cell Lung Cancer (SCLC) Market by Type
13.4.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.5 Italy Small Cell Lung Cancer (SCLC) Market Overview
13.5.1 Small Cell Lung Cancer (SCLC) Market by Type
13.5.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.6 Spain Small Cell Lung Cancer (SCLC) Market Overview
13.6.1 Small Cell Lung Cancer (SCLC) Market by Type
13.6.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.7 United Kingdom Small Cell Lung Cancer (SCLC) Market Overview
13.7.1 Small Cell Lung Cancer (SCLC) Market by Type
13.7.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
14 Japan Small Cell Lung Cancer (SCLC) Market
14.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
14.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
14.3 Small Cell Lung Cancer (SCLC) Market by Type
14.4 Small Cell Lung Cancer (SCLC) Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Teva Pharmaceutical Industries Ltd.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Sanofi
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 F. Hoffmann-La Roche Ltd.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Mylan N.V.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Pfizer Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 GSK plc
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Novartis AG
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bayer AG
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Sun Pharmaceutical Industries Ltd.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Aurobindo Pharma
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Lupin
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Merck & Co. Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 CLOVIS Oncology
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Johnson & Johnson Private Limited
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Lilly
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Small Cell Lung Cancer (SCLC) Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security